Trials / Completed
CompletedNCT00943449
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- 4SC AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to Sorafenib monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 4SC-201 | oral administration |
| DRUG | Sorafenib | oral administration |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2012-06-01
- Completion
- 2013-09-01
- First posted
- 2009-07-22
- Last updated
- 2014-01-16
Locations
15 sites across 2 countries: Germany, Italy
Source: ClinicalTrials.gov record NCT00943449. Inclusion in this directory is not an endorsement.